TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06633003: Effects of Oral Administration of Antrodia Cinnamomea Products for Clinical Symptoms in Spinocerebellar Ataxia Patients

Sponsor: ALPS Biotech CO. LTD · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 60 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT06633003 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06633003 Rescue Dossier →